Adaptive Biotechnologies Q2 net loss widens to $39.9 million; revenue rises 22% to $71.6 million

Reuters2026/07/29 20:28

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Adaptive Biotechnologies posted Q2 revenue of USD 71.6 million, up 22% year over year, while net loss widened to USD 39.9 million.
MRD revenue rose 33% to USD 66.2 million, making up 92% of revenue; Immune Medicine revenue fell 40% to USD 5.4 million.
clonoSEQ test volume increased 43% to 36,111 tests delivered.
Non-GAAP adjusted EBITDA loss narrowed to USD 0.7 million from a loss of USD 7.2 million a year earlier.
Raised full-year 2026 MRD revenue guidance to USD 268 million-USD 278 million; announced plans to separate MRD and Immune Medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607291605PRIMZONEFULLFEED9800319) on July 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Adaptive Biotechnologies Q2 net loss widens to $39.9 million; revenue rises 22% to $71.6 million

You may also like

Crypto prices